PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business

Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail

Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.

7sources
7articles
5velocity
+65%since first seen
20d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

Novartis took a $1.9 billion writedown following a drug trial failure involving del-desiran after its Avidity acquisition, alongside a broader $2.2 billion hit from drug trial setbacks. Despite these financial impacts on profit, the CEO maintained confidence in the acquisition and long-term revenue goals.

Consequently, the company raised its annual profit guidance.

Epilogue added 16d ago, after coverage quieted.

The brief

Recent business reporting details a significant financial and clinical development involving pharmaceutical company Novartis. According to coverage from outlets including BioSpace, the Wall Street Journal, Fierce Pharma, the Financial Times, FirstWord Pharma, Reuters, and Fierce Biotech, Novartis is managing a $1.9 billion hit tied to the failure of the drug del-desiran. Additional reporting from Reuters notes a broader total financial impact of $2.2 billion stemming from various drug trial setbacks. Despite these substantial write-downs and trial failures, the leadership at Novartis has expressed continued confidence in its broader corporate strategy, specifically maintaining faith in a twelve billion dollar acquisition involving Avidity. Media coverage heavily emphasizes the resilience of the company's executive leadership in the face of these high-profile clinical failures.

The Financial Times and Fierce Pharma highlight that the chief executive officer remains unfazed by the setbacks, keeping long-term revenue goals intact. Simultaneously, financial reporting from the Wall Street Journal, FirstWord Pharma, and Reuters points out that Novartis has chosen to raise its annual profit guidance. This juxtaposition of substantial drug trial writedowns alongside lifted financial guidance forms the primary focus of the business reporting across all seven tracked news sources. This unfolding situation builds upon prior corporate actions and major financial investments by Novartis, most notably the blockbusting twelve billion dollar acquisition of Avidity. The recent clinical failure of del-desiran represents a major hurdle following that acquisition, testing the pharmaceutical firm's broader pipeline and financial resilience.

Coverage does not yet specify the exact operational steps researchers will take next regarding the failed drug, but the current reporting establishes that the company's long-term financial planning remains anchored despite the immediate losses. Observers and market analysts will be tracking subsequent corporate announcements to monitor how Novartis navigates its updated profit guidance and integrates its major acquisitions following these trials. While current headlines establish the immediate financial hits and leadership responses, future coverage will likely determine the longer-term market repercussions of the del-desiran setback. Readers should consult ongoing financial reports for updates on how the company manages its remaining portfolio in light of these multi-billion dollar adjustments.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 18d ago.

Quick answers

What caused the financial hit for Novartis?

Coverage states the hit stems from drug trial setbacks, specifically including a failure of the drug del-desiran.

Did the financial losses alter Novartis's profit expectations?

No, according to coverage, Novartis actually raised its annual profit guidance despite the setbacks.

How does leadership view the Avidity acquisition following the trial failure?

Coverage indicates the CEO maintains confidence in the twelve billion dollar buy and remains unfazed by the clinical failures.

Coverage (7)

Topics

Related trends

\n \n \n \n \n \n \n